Top 5 Adolescent Medicine Apps for Primary Care

Semaglutide 2.4 mg significantly lowered the risk of MACE and mortality in patients with ASCVD and overweight or obesity but without diabetes, researchers reported.

“I think it’s important to have a lot of tools in our toolbox, and [tapinarof cream 1%] is one that gives us great flexibility," said Linda Stein Gold, MD.

Findings of the EXSTROM trial may help elucidate the mechanism by which low-dose colchicine prevents MI and stroke in adults with established CAD, experts suggest.

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

Your daily dose of the clinical news you may have missed.

The results seen with the only oral GLP-1 receptor agonist reflect "a profound clinical impact" for adults at high risk for MACE who are averse to injectable therapy.